858676-60-5

Basic information

• Product Name: 1-(4-IODOBENZYL)PYRROLIDINE
• Synonyms: 1-(4-IODOBENZYL)PYRROLIDINE;1-(4-Iodobenzyl)pyrrolidine 97%;1-(4-Iodobenzyl)pyrrolidine97%
• CAS NO: 858676-60-5
• Molecular Formula: C₁₁H₁₄IN
• Molecular Weight: 287.14
• Mol File: 858676-60-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 288.2 °C at 760 mmHg
• Flash Point: 128.1 °C
• Appearance: /
• Density: 1.593g/cm³
• Vapor Pressure: 0.00237mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 1-(4-IODOBENZYL)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-IODOBENZYL)PYRROLIDINE(858676-60-5)
• EPA Substance Registry System: 1-(4-IODOBENZYL)PYRROLIDINE(858676-60-5)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 858676-60-5(Hazardous Substances Data)

Usage

General Description

1-(4-iodobenzyl)pyrrolidine is a chemical compound with the molecular formula C12H15IN. It is a pyrrolidine derivative that contains an iodobenzyl group attached to the nitrogen atom. 1-(4-IODOBENZYL)PYRROLIDINE is used in organic synthesis and pharmaceutical research as a building block for the preparation of various biologically active molecules. It is also used as an intermediate in the production of pharmaceuticals and agrochemicals. 1-(4-iodobenzyl)pyrrolidine is a white to off-white crystalline solid with a molecular weight of 281.16 g/mol. It is important to handle this compound with proper safety precautions due to its potential hazards, including irritation to the eyes, skin, and respiratory system.

InChI:InChI=1/C11H14IN/c12-11-5-3-10(4-6-11)9-13-7-1-2-8-13/h3-6H,1-2,7-9H2

Upstream product

• 123-75-1 pyrrolidine 
• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 168317-99-5 (4-iodophenyl)(pyrrolidin-1-yl)methanone 
• 619-58-9 4-iodobenzoic acid 

Downstream Products

• 630385-38-5 1-[1-(4-iodophenyl)-1-(methyl)ethyl]pyrrolidine 
• 1394862-48-6 1,3-bis(2-(4-(pyrrolidin-1-ylmethyl)phenyl)oxazol-5-yl)benzene 
• 858677-31-3 1-{4-[(trimethylsilyl)ethynyl]benzyl}pyrrolidine 

Relevant articles and documents

A practical catalytic reductive amination of carboxylic acids

We report reductive alkylation reactions of amines using carboxylic acids as nominal electrophiles. The two-step reaction exploits the dual reactivity of phenylsilane and involves a silane-mediated amidation followed by a Zn(OAc)2-catalyzed amide reduction. The reaction is applicable to a wide range of amines and carboxylic acids and has been demonstrated on a large scale (305 mmol of amine). The rate differential between the reduction of tertiary and secondary amide intermediates is exemplified in a convergent synthesis of the antiretroviral medicine maraviroc. Mechanistic studies demonstrate that a residual 0.5 equivalents of carboxylic acid from the amidation step is responsible for the generation of silane reductants with augmented reactivity, which allow secondary amides, previously unreactive in zinc/phenylsilane systems, to be reduced.

Borinic Acid Catalysed Reduction of Tertiary Amides with Hydrosilanes: A Mild and Chemoselective Synthesis of Amines

A reduction of various aryl, alkyl, and α,β-unsaturated amides with phenylsilane, catalysed by a borinic acid, is reported. The unprecedented reaction was carried out under very mild conditions and led to useful amines. Furthermore, the reaction tolerates a variety of functional groups. Initial investigations implicated that an intermediate diarylhydroborane is involved in the reaction mechanism.

3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS

The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R1, R2 and R3 have significances given in a claim 1. In addition, said invention relates to drugs containing at least one type of inventive amid. Because of the antagonist activity of an MCH-receptor, the inventive drugs are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.